| Title: |
Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan. |
| Authors: |
Omori, Masashi, Shibuya, Tomoyoshi, Ishino, Hirotaka, Fukuo, Yuka, Odakura, Rina, Koma, Masao, Maruyama, Takafumi, Ito, Kentaro, Haraikawa, Mayuko, Nomura, Kei, Yano, Shintaro, Nomura, Osamu, Ishikawa, Dai, Hojo, Mariko, Osada, Taro, Nagahara, Akihito |
| Source: |
Biomedicines; May2024, Vol. 12 Issue 5, p1119, 13p |
| Subject Terms: |
ULCERATIVE colitis, INFLAMMATORY bowel diseases, MONOCYTE lymphocyte ratio, BODY mass index, REMISSION induction |
| Geographic Terms: |
JAPAN |
| Abstract: |
Ustekinumab (UST) is an anti–IL-12/23p40 monoclonal antibody used to treat inflammatory bowel disease. The aim of this retrospective, multicenter study was to investigate the effectiveness of UST administration in achieving remission in patients with ulcerative colitis (UC) and to determine patient characteristics that influence its effectiveness. Of 88 UC patients who received UST from March 2020 to August 2023, 47 with traceable data and for whom 56 weeks had elapsed since the start of treatment received UST to induce remission. The remission rates at 8 weeks were 66% overall, 73.7% for Bio Naïve (never used biologics/JAK inhibitors), and 60.7% for Bio Failure (used biologics/JAK inhibitors) groups. Remission rates at 56 weeks were 70.2% overall, 73.7% for Bio Naïve, and 67.9% for Bio Failure groups. Ustekinumab showed good mid-to-long-term results in the induction of remission of UC in both Bio Naïve and Bio Failure groups. The group showing remission at 8 weeks had a significantly higher non-relapse or continuation rate (proportion of patients with no worsened symptoms necessitating surgery/drug change) at 56 weeks. Predictive factors for achieving remission after UST in UC were female gender, low body mass index, and low lymphocyte-to-monocyte ratio. Thus, UST is effective for moderate-to-severe UC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Biomedicines is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
